Connor, Clark & Lunn Investment Management Ltd. Biotechnology

Connor, Clark & Lunn Investment Management Ltd.

$28.9 Billion
Q3 2025

Stock List

Stock	Market Cap.	Holding Value (Reported)	# of Shares.	Last Trade	Trade History
VRTX Vertex Pharmaceuticals Inc	$111B	$86.5 Million 0.3% of portfolio	220,801	Q3 2025 Added 7.14%
IONS Ionis Pharmaceuticals Inc	$10.2B	$57.4 Million 0.2% of portfolio	878,155	Q3 2025 Added 230.39%
MDGL Madrigal Pharmaceuticals, Inc.	$9.05B	$39.3 Million 0.14% of portfolio	85,773	Q3 2025 Reduced 14.31%
MIRM Mirum Pharmaceuticals, Inc.	$2.63B	$36.4 Million 0.13% of portfolio	495,976	Q3 2025 Added 17.05%
SRPT Sarepta Therapeutics, Inc.	$1.65B	$33.6 Million 0.12% of portfolio	1,745,051	Q3 2025 Added 183.54%
CORT Corcept Therapeutics Inc	$8.09B	$30.7 Million 0.11% of portfolio	369,869	Q3 2025 Added 16.31%
AXSM Axsome Therapeutics, Inc.	$5.99B	$25.4 Million 0.09% of portfolio	209,069	Q3 2025 Reduced 6.97%
AGIO Agios Pharmaceuticals, Inc.	$2.39B	$21.3 Million 0.07% of portfolio	530,098	Q3 2025 Added 4.92%
BMRN Biomarin Pharmaceutical Inc	$10.2B	$21.2 Million 0.07% of portfolio	390,637	Q3 2025 Reduced 3.2%

TVTX Travere Therapeutics, Inc.	$2.21B	$20.5 Million 0.07% of portfolio	857,899	Q3 2025 Added 25.15%
FOLD Amicus Therapeutics, Inc.	$2.66B	$15.9 Million 0.06% of portfolio	2,019,556	Q3 2025 Added 9.8%
IMVT Immunovant, Inc.	$3.55B	$15.4 Million 0.05% of portfolio	558,897	Q3 2025 Added 24.61%
AMLX Amylyx Pharmaceuticals, Inc.	$743M	$15 Million 0.05% of portfolio	1,107,008	Q3 2025 Reduced 4.11%
ACAD Acadia Pharmaceuticals Inc	$3.89B	$14.3 Million 0.05% of portfolio	668,363	Q3 2025 Added 4.03%
VKTX Viking Therapeutics, Inc.	$3.05B	$13.9 Million 0.05% of portfolio	544,201	Q3 2025 Added 21.69%
XERS Xeris Biopharma Holdings, Inc.	$986M	$13.8 Million 0.05% of portfolio	1,698,757	Q3 2025 Added 38.34%
JAZZ Jazz Pharmaceuticals PLC	$8.84B	$12.3 Million 0.04% of portfolio	93,173	Q3 2025 Reduced 33.91%
RYTM Rhythm Pharmaceuticals, Inc.	$5.54B	$12.2 Million 0.04% of portfolio	121,260	Q3 2025 Added 5.34%

INCY Incyte Corp	$23.2B	$9.45 Million 0.03% of portfolio	111,414	Q3 2025 Reduced 75.69%
RVMD Revolution Medicines, Inc.	$5.94B	$8.93 Million 0.03% of portfolio	191,327	Q3 2025 Added 485.19%
MNKD Mannkind Corp	$1.3B	$7.96 Million 0.03% of portfolio	1,481,807	Q3 2025 Added 8.19%
INSM Insmed Inc	$26.2B	$7.44 Million 0.03% of portfolio	51,658	Q3 2025 Reduced 77.16%
BCRX Biocryst Pharmaceuticals Inc	$1.32B	$6.44 Million 0.02% of portfolio	848,562	Q3 2025 Reduced 32.53%
HRMY Harmony Biosciences Holdings, Inc.	$2.01B	$6.39 Million 0.02% of portfolio	231,896	Q3 2025 Reduced 6.82%
TARS Tarsus Pharmaceuticals, Inc.	$1.92B	$6.17 Million 0.02% of portfolio	103,811	Q3 2025 Added 71.6%
AUPH Aurinia Pharmaceuticals Inc.	$2.18B	$5.98 Million 0.02% of portfolio	541,188	Q3 2025 Reduced 16.76%
RPRX Royalty Pharma PLC	$17.1B	$5.89 Million 0.02% of portfolio	166,984	Q3 2025 Added 861.56%
KROS Keros Therapeutics, Inc.	$445M	$5.3 Million 0.02% of portfolio	335,154	Q3 2025 Added 26.14%
PBYI Puma Biotechnology, Inc.	$226M	$4.84 Million 0.02% of portfolio	943,472	Q3 2025 Added 4.8%
VNDA Vanda Pharmaceuticals Inc.	$246M	$4.51 Million 0.02% of portfolio	904,544	Q3 2025 Added 4.16%
ARWR Arrowhead Pharmaceuticals, Inc.	$4.37B	$4.3 Million 0.01% of portfolio	124,529	Q3 2025 New
CDXC Chroma Dex Corp.	$420M	$3.86 Million 0.01% of portfolio	627,879	Q3 2025 Reduced 23.74%
FULC Fulcrum Therapeutics, Inc.	$451M	$3.35 Million 0.01% of portfolio	384,138	Q3 2025 Added 12.14%
VTYX Ventyx Biosciences, Inc.	$523M	$3.3 Million 0.01% of portfolio	1,059,823	Q3 2025 Added 12.13%
KURA Kura Oncology, Inc.	$749M	$3.23 Million 0.01% of portfolio	364,932	Q3 2025 New
ETON Eton Pharmaceuticals, Inc.	$428M	$3.14 Million 0.01% of portfolio	143,811	Q3 2025 Reduced 35.24%
AKBA Akebia Therapeutics, Inc.	$313M	$2.76 Million 0.01% of portfolio	1,020,668	Q3 2025 Reduced 13.56%
TBPH Theravance Biopharma, Inc.	$1.16B	$2.55 Million 0.01% of portfolio	174,837	Q3 2025 Added 208.83%
RARE Ultragenyx Pharmaceutical Inc.	$2.32B	$2.37 Million 0.01% of portfolio	78,922	Q3 2025 Added 1,241.07%
INVA Innoviva, Inc.	$1.55B	$2.35 Million 0.01% of portfolio	128,759	Q3 2025 Added 63.19%
VCYT Veracyte, Inc.	$2.82B	$2.22 Million 0.01% of portfolio	64,577	Q3 2025 Reduced 76.87%
NUVL Nuvalent, Inc.	$4.15B	$2.06 Million 0.01% of portfolio	23,787	Q3 2025 New
NVO Novo Nordisk A S	$109B	$1.96 Million 0.01% of portfolio	35,258	Q3 2025 Added 73.51%
KRYS Krystal Biotech, Inc.	$5.29B	$1.73 Million 0.01% of portfolio	9,778	Q3 2025 New
CYTK Cytokinetics Inc	$6.25B	$1.68 Million 0.01% of portfolio	30,504	Q3 2025 New
TECH Bio Techne Corp	$2.33B	$1.54 Million 0.01% of portfolio	27,765	Q3 2025 New
MDXG Mimedx Group, Inc.	$838M	$1.25 Million 0.0% of portfolio	179,424	Q3 2025 Added 24.46%
MGNX Macrogenics Inc	$94.6M	$1.21 Million 0.0% of portfolio	710,608	Q3 2025 Added 4.15%
RCUS Arcus Biosciences, Inc.	$1.45B	$1.17 Million 0.0% of portfolio	86,058	Q3 2025 New
ENTA Enanta Pharmaceuticals Inc	$250M	$927,000 0.0% of portfolio	77,506	Q3 2025 Added 423.83%

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Connor, Clark & Lunn Investment Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Connor, Clark & Lunn Investment Management Ltd. with notifications on news.